Xinnate

Xinnate is a pharmaceutical development company in Lund, Sweden developing novel, pharmaceutical therapies based on a pioneering technology of immune modulating peptides, that targets dysfunctional healing by controlling presence of microbials and the complex interplay of inflammatory responses.

Xinnate runs an ambitious research and clinical program for TCP25 including a clinical study in phase 1b in patients with Epidermolysis bullosa (EB). Late-stage clinical development and commercialization will take place in partnership with one or more leading pharmaceutical companies.